The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE^−/− Mice

Table 1

Data on body weight, fasting blood glucose, and blood lipid profile in all groups.

	DM+dapa	DM+con	NDM+dapa	NDM+con	C57
BW (g)	28.71 ± 2.58	27.05 ± 3.97	30.44 ± 2.06	32.68 ± 2.12	31.83 ± 2.66
FBG (mmol/l)		23.94 ± 2.73		12.79 ± 1.42	12.05 ± 2.24
TC (mmol/l)	34.34 ± 7.97	41.26 ± 11.75	29.56 ± 5.28	19.29 ± 7.84
TG (mmol/l)		2.14 ± 1.15	0.85 ± 0.21	0.78 ± 0.19	0.61 ± 0.23
HDL-c (mmol/l)	3.67 ± 1.05	3.50 ± 1.73	2.89 ± 0.70	2.12 ± 0.74	1.93 ± 0.19
LDL-c (mmol/l)	26.42 ± 6.75	25.71 ± 8.85	21.56 ± 4.06	18.43 ± 3.06
FFA (mmol/l)		1.31 ± 0.34	0.92 ± 0.23	0.83 ± 0.24	0.77 ± 0.10

Diabetic mice that received dapagliflozin (DM+dapa), diabetic mice that received vehicle (DM+con), nondiabetic mice that received dapagliflozin (NDM+dapa), nondiabetic mice that received vehicle (NDM+con), and wild-type (C57/BL6) mice were measured. BW: body weight; FBG: fasting blood glucose; TC: total cholesterol; TG: triglycerides; HDL-c: HDL cholesterol; LDL-c: LDL cholesterol; FFA: free fat acid; values are expressed as mean ± SD, per group. , ; , versus DM+con; , versus NDM+con; &&, versus NDM+con.